- Home
- OTLY vs AVIR Comparison
OTLY vs AVIR Comparison
Compare OTLY & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- AVIR
- Stock Information
- Founded
- OTLY 1994
- AVIR 2012
- Country
- OTLY Sweden
- AVIR United States
- Employees
- OTLY N/A
- AVIR N/A
- Industry
- OTLY Packaged Foods
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- OTLY Consumer Staples
- AVIR Health Care
- Exchange
- OTLY Nasdaq
- AVIR Nasdaq
- Market Cap
- OTLY 303.5M
- AVIR 273.0M
- IPO Year
- OTLY 2021
- AVIR 2020
- Fundamental
- Price
- OTLY $15.07
- AVIR $3.47
- Analyst Decision
- OTLY Buy
- AVIR Hold
- Analyst Count
- OTLY 5
- AVIR 1
- Target Price
- OTLY $19.60
- AVIR $6.00
- AVG Volume (30 Days)
- OTLY 158.4K
- AVIR 379.3K
- Earning Date
- OTLY 07-23-2025
- AVIR 08-07-2025
- Dividend Yield
- OTLY N/A
- AVIR N/A
- EPS Growth
- OTLY N/A
- AVIR N/A
- EPS
- OTLY N/A
- AVIR N/A
- Revenue
- OTLY $828,200,000.00
- AVIR N/A
- Revenue This Year
- OTLY $4.68
- AVIR N/A
- Revenue Next Year
- OTLY $4.78
- AVIR N/A
- P/E Ratio
- OTLY N/A
- AVIR N/A
- Revenue Growth
- OTLY 4.43
- AVIR N/A
- 52 Week Low
- OTLY $6.00
- AVIR $2.46
- 52 Week High
- OTLY $20.80
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- OTLY 65.35
- AVIR 46.31
- Support Level
- OTLY $14.30
- AVIR $3.36
- Resistance Level
- OTLY $15.50
- AVIR $3.97
- Average True Range (ATR)
- OTLY 0.77
- AVIR 0.19
- MACD
- OTLY -0.02
- AVIR -0.02
- Stochastic Oscillator
- OTLY 83.15
- AVIR 16.67
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).